Senility Patents (Class 514/879)
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 8029826
    Abstract: The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: October 4, 2011
    Assignee: The Regents of the University of California
    Inventor: Michael S. McGrath
  • Patent number: 7964220
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 21, 2011
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7867487
    Abstract: Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: January 11, 2011
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Beka Solomon, Orna Goren
  • Patent number: 7858602
    Abstract: A method for the treatment and prophylaxis of conditions of aging due oxidative stress and as growth factors of stem cells. Such conditions due to oxidative stress are associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes in the tissue of a subject. Such conditions include but are not limited to alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, diabetes mellitus, amyloid diseases, atherosclerosis, arthritis, osteoporosis, cystic fibrosis. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of one or more compounds that increases the presence of one or more Carbonic Anhydrase Isozymes whose levels have been reduced in the subject.
    Type: Grant
    Filed: May 12, 2007
    Date of Patent: December 28, 2010
    Inventor: Victorio C. Rodriguez
  • Patent number: 7708990
    Abstract: The object of the present invention is to provide a composition maintaining a blood coenzyme Q concentration at a high level in blood for a prolonged period of time, in order to surely attain an effect of coenzyme Q, which can be expected to manifest a superior effect in maintaining health in humans and animals. By using a composition which comprises a coenzyme Q being a mixture of a reduced coenzyme Q and an oxidized coenzyme Q with the proportion of the reduced coenzyme Q to the whole coenzyme Q of more than 95% by weight, the present invention can attain a high maximum blood concentration of a coenzyme Q as well as long maintenance of high concentration of coenzyme Q in blood for a prolonged period of time, and the area under the blood concentration curve (AUC) can be expanded.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: May 4, 2010
    Assignee: Kaneka Corporation
    Inventors: Kenji Fujii, Taizo Kawabe, Hiroshi Kubo
  • Patent number: 7595308
    Abstract: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some cases, the composition may include a silanol, a silandiol, a silantriol, or a cyclic organosilane, and/or be able to form a silanol, a silandiol, or a silantriol upon exposure to physiological conditions such as are found in the blood, in the stomach and/or gastrointestinal tract, or in the brain or other organ. In certain cases, the organosilicon compound may be bound to a moiety able to be transported across the blood-brain barrier into the brain, for example, an amino acid, a peptide, a protein, a virus, etc. The organosilicon compound may also be labeled (e.g., fluorescently or radioactively) in certain instances.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: September 29, 2009
    Assignee: GrenPharma LLC
    Inventors: Orrie Friedman, Ivan Correia, Toby Sommer, David Alan Kew
  • Patent number: 7378111
    Abstract: Provided is a novel use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3), including lithium or any other GSK-3 inhibitor, to block, reduce or inhibit processing of amyloid precursor proteins to beta-amyloid (A?) peptides, which are now believed to be the principal cause of Alzheimer's disease, thereby providing methods useful for the prevention, inhibition or reversal of the disease. Also provided are methods of using agents that specifically target the ? isoform of GSK-3, which is responsible for APP processing, making such selective GSK-3?-specific inhibitors especially useful in the treatment, prevention, and possible reversal of Alzheimer's disease. Further provided are kits and screening methods associated with the present methods.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: May 27, 2008
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christopher J. Phiel, Christina A. Wilson, Virginia M-Y. Lee, Peter S. Klein
  • Patent number: 7365049
    Abstract: The use of Afamin, in particular in combination with vitamin E is described for producing a preparation for the treatment of oxidative stress.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: April 29, 2008
    Assignee: Vitateg Biotechnology GmbH
    Inventors: Michael Becker-Andre, Hans Dieplinger, Charlotte Teunissen, Lidija Jerkovic
  • Patent number: 7256184
    Abstract: A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes. Such conditions include chronic neurodegenerative conditions including dementia such as Alzheimer's disease. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of a compound that increases the presence of one or more cell-specific carbonic anhydrase enzymes whose levels are reduced in the patient. Such compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: August 14, 2007
    Inventor: Victorio C. Rodriguez
  • Patent number: 7244708
    Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined and were used to design substrate analogs of the natural -2 substrate that can inhibit the function of memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. The inhibition constant of OM99-2 is 1.6×10?9 M against recombinant pro-memapsin 2. Crystallography of memapsin 2 bound to this inhibitor was used to determine the three dimensional structure of the protein, and the importance of the various residues in binding. This information is useful for designing new inhibitors to memapsin 2, for diagnosing and treating and/or preventing Alzheimer's disease.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: July 17, 2007
    Assignees: Oklahoma Medical Research Foundation, The Board of Trustees of the University of Illinois
    Inventors: Jordan J. N. Tang, Arun K. Ghosh
  • Patent number: 7011854
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: March 14, 2006
    Assignee: Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda
    Inventors: Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 6821997
    Abstract: A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of cell-specific carbonic anhydrase enzymes in the brain, such as conditions associated with chronic neurodegenerative conditions including dementia such as Alzheimer's disease, which method includes the administering over an extended period of time, ranging from 6 months to 5 years, of a pharmaceutically effective, non-toxic amount of a compound that increases the presence of cell-specific carbonic anhydrase enzymes in the brain. That compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: November 23, 2004
    Inventor: Victorio C. Rodriguez
  • Patent number: 6759049
    Abstract: The invention concerns the field of pharmaceutics and dietetics. More particularly, the invention concerns pharmaceutical and/or dietetic mushroom-based compositions, characterised in that they contain one or several edible mushrooms with therapeutic properties and chitosan.
    Type: Grant
    Filed: February 25, 2001
    Date of Patent: July 6, 2004
    Assignee: Medecine Information Formation S.A.
    Inventor: Bruno Donatini
  • Patent number: 6660757
    Abstract: The invention concerns the use of riluzole or one of its pharmaceutically acceptable salts for preventing and/or treating acoustic traumas and, in particular, different types of deafness and tinnitus.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: December 9, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Jean-Marie Stutzmann, John Randle
  • Patent number: 6608064
    Abstract: The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: August 19, 2003
    Assignee: Pfizer Inc
    Inventors: Stafford McLean, Stevin H. Zorn, Elisa R. Jackson
  • Patent number: 6599935
    Abstract: The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: July 29, 2003
    Assignee: University of Virginia Patent Foundation
    Inventor: Timothy L. Macdonald
  • Patent number: 6596709
    Abstract: The invention relates to a compound of formula (I): wherein: X represents chlorine or fluorine or CF3, R represents hydrogen or a group and methods for using the same.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: July 22, 2003
    Assignee: Les Laboratoires Servier
    Inventors: Alex Cordi, Patrice Desos, Pierre Lestage
  • Patent number: 6552087
    Abstract: The use of (+)-sibutramine in the treatment of depression, obesity, Parkinson's disease, cerebral function disorders and diabetes is described.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: April 22, 2003
    Assignee: Abbott GmbH & Co. KG
    Inventors: Sharon C. Cheetham, David John Heal
  • Patent number: 6509381
    Abstract: A composition is prepared by extracting and isolating phytochemical fractions from plant matter for treatment for neurological conditions and especially for migraine headaches, inflammations, dementia, and Alzheimer's Disease. The composition is enriched, preferably with two or more different fractions, namely: isoflavones, lignans, saponins and saponogenins, catechins, and phenolic acids. The two selected fractions are different from each other and are combined specifically to form a composition to treat a neurological condition. Soy is the preferred source of these phytochemicals; however, other plants may also be used, such as wheat, psyllium, rice, oats, red clover, kudzu, alfalfa, flax, and cocoa. The composition may be delivered in an easy to use or consume form, such as cream, pills, tablets, capsules, pellets, dry powder, health bars, food ingredients and supplements, soft gels, and the like.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: January 21, 2003
    Assignee: Archer Daniels Midland Company
    Inventors: Mark Empie, Eric Gugger
  • Patent number: 6506746
    Abstract: The invention provides a method of treating a cognitive dysfunction comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b][1,5]benzodiazepine.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: January 14, 2003
    Assignee: Eli Lilly and Company
    Inventor: Charles M Beasley, Jr.
  • Patent number: 6458820
    Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: October 1, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Edward Dallas Hall, Philip F. Von Voigtlander, Frank A. Rohde
  • Patent number: 6391310
    Abstract: A composition is prepared by extracting phytochemicals from plant matter and is administered to provide treatment for mental conditions and nerve problems, especially neurological symptoms, immunological symptoms, migraine headaches, inflammations and dementia. This composition is enriched preferably with two or more fractions of plant matter, namely: isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids. The isoflavones are taken from a group including malonyl, acetyl, glucoside and aglycone. Soy is the preferred source of these chemicals; however, other plants may also be used, such as wheat, psyllium, rice, oats, red clover, kudzu, alfalfa, flax, and cocoa. The composition is a dietary supplement for treatment of various syndromes and disorders presented in a concentrated, easily delivered and consumed dosage, such as a health bar.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: May 21, 2002
    Assignee: Archer Daniels Midland Company
    Inventors: Mark Empie, Eric Gugger
  • Patent number: 6380267
    Abstract: A method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, comprising selecting a patient having at least one sign or symptom selected from the group consisting of akinesia, bradykinesia, dyskinesias, gait disturbances, posture disturbances, rigid limbs, speech impairments and tremor and administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: April 30, 2002
    Inventor: David M. Swope
  • Patent number: 6358527
    Abstract: The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: March 19, 2002
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Paul Marie Victor Gilis, Valentin Florent Victor De Condé
  • Patent number: 6350467
    Abstract: A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: February 26, 2002
    Assignee: Antioxidant Pharmaceuticals Corp.
    Inventors: Harry B. Demopoulos, Myron L. Seligman
  • Patent number: 6348213
    Abstract: A method of-treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: February 19, 2002
    Assignees: Yissum Research and Development Co. of The Hebrew University of Jerusalem, Hadassah Medical Organization
    Inventors: Yechezkel Barenholz, Elishalom Yechiel
  • Patent number: 6342515
    Abstract: The present invention provides a medicament for neurodegenerative diseases comprising zonisamide or an alkali metal salt thereof as an active ingredient. The present medicament can be used in the prevention and treatment of neurodegenerative diseases such as Parkinson's disease, Huntington's disease, choreic syndrome and dystonic syndrome in mammals (including human).
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: January 29, 2002
    Assignee: Dainippon Pharmaceutical Co., Ltd.
    Inventors: Yoshinobu Masuda, Yoshiaki Ochi
  • Patent number: 6300329
    Abstract: The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: October 9, 2001
    Inventors: Stafford McLean, Steven H. Zorn, Elisa R. Jackson
  • Patent number: 6277886
    Abstract: Pharmaceutical compositions for the treatment of a neurological disorder of neurotrauma or for improving memory in a patient comprising a therapeutically effective amount of S-(−)-N-proparygl-1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. The pharmaceutical compositions are adapted, in particular for treating a neurological hypoxia or anoxia, neurodegenerative diseases. Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage.
    Type: Grant
    Filed: January 11, 1999
    Date of Patent: August 21, 2001
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.
    Inventors: Ruth Levy, Moussa B. H. Youdim, John P. M. Finberg, Sasson Cohen, Jeff Sterling
  • Patent number: 6254853
    Abstract: This invention provides esters of propofol (2,6,-diisoprophenol). The propofol esters are soluble in water and metabolize rapidly to propofol in the body. The propofol esters are useful as pro-drugs for the same indications as propofol. This invention also provides methods of treating neurodegenerative diseases by administering as effective amount of propofol.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: July 3, 2001
    Assignee: Vyrex Corporation
    Inventors: Sheldon S. Hendler, Robert A. Sanchez, Jan Zielinski
  • Patent number: 6238689
    Abstract: A delayed and sustained release composition of an additive and/or toxic agent such as nicotine is delivered systemically in therapeutic amounts while avoiding the peak plasma levels which gives rise to addiction and/or toxic side effects. The composition is delivered for absorption predominantly from the colon.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: May 29, 2001
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: John Rhodes, Brian K. Evans, Peter Rhodes, William J. Sandborn
  • Patent number: 6187756
    Abstract: It has been discovered that the stimulation of &bgr;-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising &bgr;-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by &bgr;-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of &bgr;-adrenergic receptors.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: February 13, 2001
    Assignee: The Massachusetts Institute of Technology
    Inventors: Robert K. K. Lee, Richard J. Wurtman
  • Patent number: 6184255
    Abstract: The present invention has for its object to provide a medicinal composition comprising coenzyme Q10 as an active ingredient, which composition features an enhanced absorption after oral administration. The present invention is directed to a medicinal composition comprising coenzyme Q10 as an active ingredient with the reduced form of coenzyme Q10 accounting for more than 20 weight % of said coenzyme Q10.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: February 6, 2001
    Assignee: Kaneka Corporation
    Inventors: Tatsumasa Mae, Yoshitomo Sakamoto, Souichi Morikawa, Takayoshi Hidaka
  • Patent number: 6180678
    Abstract: A method of treating age related behavorial problems in dogs is disclosed. The method involves administering adrafinil or a metabolite thereof to an animal in need of such treatment.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: January 30, 2001
    Assignee: V{acute over (e)}toquinol S.A.
    Inventors: William Norton Milgram, Christina Teresa Siwak, Fredrique Woebrle-Fontaine, Beth Anne Adams, Philippe Gruet
  • Patent number: 6159500
    Abstract: A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: December 12, 2000
    Assignee: Antioxidant Pharmaceuticals Corporation
    Inventors: Harry B. Demopoulos, Myron L. Seligman
  • Patent number: 6156777
    Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: December 5, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventors: Edward Dallas Hall, Philip F. Von Voigtlander, Frank A. Rohde
  • Patent number: 6087372
    Abstract: The present invention provides the use of 2-(4-methoxyphenyl)-pyrazolo[4,3-c]quiniolin-3-one or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for enhancing cognition, particularly in Alzheimer's Disease, a method of enhancing cognition and pharmaceutically acceptable salts such as the hemi camphor sulfonate.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: July 11, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Gerard Raphael Dawson, Angus Murray MacLeod, Guy Ralph Seabrook
  • Patent number: 6077852
    Abstract: The present invention provides a method of treating depression, mood swings, or Alzheimer's disease in a patient in need of such treatment by administering a selective estrogen receptor modulating compound of the formula ##STR1## in which R.sup.1 and R.sup.2 are independently hydroxy and alkoxy of one to four carbon atoms; and R.sup.3 and R.sup.4 are independently methyl or ethyl, or R.sup.3 and R.sup.4, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl-pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: June 20, 2000
    Assignee: Eli Lilly and Company
    Inventors: Kelly Renee Bales, Henry Uhlman Bryant, Steven Marc Paul, Mary Patricia Knadler
  • Patent number: 5866160
    Abstract: The present invention relates to a composition of soft-shelled turtles and tortoises (TT composition) and a method for the preparation of the same. It also relates to the extensive use which is beneficial to human being.
    Type: Grant
    Filed: September 3, 1996
    Date of Patent: February 2, 1999
    Assignee: Hainan Life-Nourishing Pharmacy Co.
    Inventors: Mengxue Hong, Shanshan Zhong
  • Patent number: 5843892
    Abstract: The protein, cholinergic neuronal differentiation factor (CDF), also known as leukemia inhibitory factor (LIF), is described, together with the use of the polypeptide to stimulate neuron growth and survival in animals either by direct administration or by autotransplantation of adrenal medullary cells converted to the cholinergic phenotype.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: December 1, 1998
    Assignee: California Institute of Technology
    Inventor: Paul H. Patterson
  • Patent number: 5795880
    Abstract: The invention describes a method and composition for treating obesity or related disorders in animals using an anorectic agent and dehydroepiandrosterone (DHEA). The composition effectively diminishes caloric intake, may alter metabolism, weight gain, or a combination thereof.
    Type: Grant
    Filed: December 30, 1996
    Date of Patent: August 18, 1998
    Assignee: Louisiana State University Medical Center Foundation
    Inventors: Frank Svec, Johnny Porter
  • Patent number: 5716632
    Abstract: In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridones. The composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: February 10, 1998
    Inventor: Solomon B. Margolin
  • Patent number: 5668117
    Abstract: Therapeutic compositions comprising an effective amount of at least one carbonyl trapping agent alone or in combination with a therapeutically effective of a co-agent or medicament are disclosed. The compositions are used to treat a mammal suffering from a neurological disease characterized by covalent bond crosslinking between the nerve cells, other cellular structures and their intracellular and extracellular components, with disease induced carbonyl-containing aliphatic or aromatic hydrocarbons present in mammals.
    Type: Grant
    Filed: June 29, 1993
    Date of Patent: September 16, 1997
    Inventor: Howard K. Shapiro
  • Patent number: 5650420
    Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.
    Type: Grant
    Filed: December 15, 1994
    Date of Patent: July 22, 1997
    Assignees: Pharmacia & Upjohn Company, Boehringer Ingelheim International GmbH
    Inventors: Edward D. Hall, Philip F. Von Voigtlander, Frank A. Rohde
  • Patent number: 5589182
    Abstract: A pharmaceutical composition suitable for the treatment of a condition selected from the group consisting of cardiovascular disease, cerebrovascular disease, Alzheimer's disease, depression or combinations thereof comprising various mixtures of the aqueous extracts of tissue of specific Chinese plants and herbs. A method of preparing the pharmaceutical compositions of the invention and a method for treating a patient therewith are also disclosed.
    Type: Grant
    Filed: December 6, 1993
    Date of Patent: December 31, 1996
    Inventors: Renki Tashiro, Ruth H. Pater
  • Patent number: 5527788
    Abstract: The invention describes a method and composition for treating obesity or related disorders in animals using an anorectic agent and dehydroepiandrosterone (DHEA). The composition effectively diminishes caloric intake, may alter metabolism, weight gain, or a combination thereof.
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: June 18, 1996
    Assignee: Louisiana State Univ. Medical Center Foundation
    Inventors: Frank Svec, Johnny Porter
  • Patent number: 5492930
    Abstract: A method for treating CNS disorders and/or improving cognitive ability in a mammal utilizing 2-phenyl-1,3-propanediol monocarbamate is disclosed. Also disclosed are formulations and methods for manufacturing this compound.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: February 20, 1996
    Assignee: Schering Corporation
    Inventor: Vicki L. Coffin
  • Patent number: 5468726
    Abstract: The administration of Somatostatin and growth hormone releasing factor at useful dosage levels alleviates the symptoms of various neuropsychiatric disorders.Growth hormone and neuropsychiatric responses to the administration of growth hormone releasing factor to mammals indicate its usefulness as an antemortem marker for senile dementia of the Alzheimer's type.
    Type: Grant
    Filed: February 23, 1990
    Date of Patent: November 21, 1995
    Assignee: Ares Holding 89 N.V.
    Inventor: Ramon Cacabelos
  • Patent number: 5468763
    Abstract: A class of Glycine B partial agonists is described for use in memory and learning enhancement or for treatment of a cognitive disorder. Preferred Glycine B partial agonists include the compound D-cycloserine and its prodrug compounds.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: November 21, 1995
    Assignee: G. D. Searle & Co.
    Inventors: Alex A. Cordi, Gail E. Handelmann, Joseph B. Monahan